Printer Friendly

QUIDEL NAMES SCOTT L. GLENN CHAIRMAN/CEO AND STEVEN T. FRANKEL PRESIDENT

 QUIDEL NAMES SCOTT L. GLENN CHAIRMAN/CEO
 AND STEVEN T. FRANKEL PRESIDENT
 SAN DIEGO, May 5 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced it has named Steven T. Frankel to the position of president and chief operating officer. Frankel's responsibilities will include product development, U.S. sales/marketing and manufacturing of QUIDEL- branded products in the United States. Simultaneously, Scott L. Glenn, formerly president/CEO, was named chairman and chief executive officer.
 "We are pleased to have Steven on board at such an important time of growth and expansion of our new QUIDEL products," said Glenn, now chairman and chief executive officer. "Steven brings to the table notable strength and versatility in the areas of sales and marketing to the medical professional and consumer markets. His leadership and experience will help to solidify our position as a recognized market leader. I, in turn, will be able to focus my attention on corporate strategic development and our international business."
 Frankel brings with him 25 years of experience, most recently as president of Becton Dickinson Asia Pacific, where he was responsible for sales and marketing for the Asian operations. Prior to establishing the Asia Pacific Division in 1985, Frankel was president of Becton Dickinson's U.S. Consumer Products Division. Frankel also had similar responsibility for B.D.'s European Consumer Products Division. These divisions presently command leadership positions in diabetes care for insulin syringes and home health care for fever measurement and ACE(R) bandages.
 "I am excited about the prospects at QUIDEL and the extensive pipeline of rapid diagnostic products, including its recently approved ovulation prediction test kit, Conceive(TM)," said Frankel. "Our goal will be to expand QUIDEL's market franchises in the areas of fertility, allergy and infectious disease testing to the primary care physician and the consumer."
 QUIDEL Corp. develops, manufactures and markets rapid, immuno- diagnostic products that provide simple, accurate and cost-effective diagnosis in the areas of human fertility, allergy, infectious disease and autoimmune disorders. These tests are designed for use without instrumentation in the physician's office, clinical laboratory and home testing markets.
 -0- 5/5/92
 /CONTACT: Mark Francois (investors) of QUIDEL, 619-552-7931; or Susan Noonan or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for QUIDEL/
 (QDEL) CO: QUIDEL Corp. ST: California IN: MTC SU: PER


EH-JL -- SD003 -- 6356 05/05/92 08:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:391
Previous Article:FORMER FAA OFFICIAL OF THE REAGAN ADMINISTRATION JOINS AIR METHODS BOARD OF DIRECTORS
Next Article:NO SLOW DOWN IN RESIDENTIAL MORTGAGE ACTIVITY FOR COUNTRYWIDE; APRIL VOLUME BREAKS $2 BILLION SECOND MONTH IN A ROW


Related Articles
QUIDEL SECURES LARGE ORDER FROM WALGREENS FOR ITS CONCEIVE(TM) ONE-STEP OVULATION PREDICTION TEST
QUIDEL ANNOUNCES MANAGEMENT TRANSITION
QUIDEL ACQUIRES MAJORITY INTEREST IN SPAIN'S INMUNO ANALITICA S.L.
QUIDEL EXPANDS EUROPEAN DISTRIBUTION; SIGNS PRODUCT LICENSING AGREEMENT FOR POLISH MARKET
QUIDEL UPDATES FDA SAFEPLAN(TM) STATUS
QUIDEL'S STOCKHOLDERS ELECT ROGER F. GREAVES AND ROCKELL N. HANKIN TO ITS BOARD OF DIRECTORS
QUIDEL APPOINTS RICHARD C.E. MORGAN CHAIRMAN OF THE BOARD OF DIRECTORS
Quidel Strengthens Management Team With Appointment of Glenn Holmes As Vice President, Sales and Marketing

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters